Sequana Medical will participate in the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools conference

Ghent, Belgium 3 February 2022 Sequana Medical SA (Euronext Brussels: SEQUA, the “Company” or “Sequana Medical”)an innovator in the treatment of diuretic-resistant fluid overload in liver disease, malignant ascites and heart failure, today announces that Ian Crosbie, Chief Executive Officer, will present at the Medtech, Digital Health, Life Science Conference and Diagnostic Tools from BTIG, taking place virtually from February 15-17, 2022.

Company presentation

  • Wednesday, February 16, 2022 at 8:00 a.m. ET / 2:00 p.m. CET

  • The presentation slides will be available on the Sequana Medical Investors site shortly after the event

Sequana Medical will meet with international investors in virtual one-on-one and small group meetings.

The events organized by BTIG are intended only for potential and existing customers of BTIG. To listen to the event live, please contact your BTIG representative.

For more information please contact:

Sequana Medical
Lies Vanneste
Investor Relations Director
Tel: +32 498 05 35 79
Email: [email protected]

LifeSci Advisors
Guillaume van Renterghem
Tel: +41 76 735 01 31
Email: [email protected]

About Sequana Medical

Sequana Medical is a commercial-stage medical device company using its alphapump® and DSR® (Direct Sodium Removal) technologies to develop innovative treatments against fluid overload in liver disease, malignant ascites and heart failure where diuretics are no longer effective. Fluid overload is a common complication of many major diseases – including advanced liver disease caused by cirrhosis and heart failure related to NASH (non-alcoholic steatohepatitis) – with resistance to diuretics being widespread. The American market for alphapump resulting from NASH-related cirrhosis is expected to exceed 3 billion per year over the next 10 to 20 years. The heart failure market for RSD and alphapump DSR® is estimated to be worth more than €5 billion per year in the US and EU5 by 2026.

the alphaThe pump is Sequana Medical’s unique, fully implanted wireless device that automatically pumps fluid from the abdominal cavity into the bladder, where it is naturally eliminated through urination. DSR is Sequana Medical’s proprietary approach to managing sodium and fluid overload through the use of a sodium-free infusate administered into the abdominal cavity.

In the United States, the Company’s main growth market, the alphaThe pump has received FDA Breakthrough Device designation for recurrent or refractory ascites due to cirrhosis of the liver. Interim data from the ongoing North American pivotal study (POSEIDON) showed positive results across all primary endpoints and rapid and persistent clinically important improvement in quality of life. All patients have been enrolled in the study and primary endpoint reporting is expected in Q4 2022. This study is intended to support a future marketing application of the alphapump in the United States and Canada. In Europe, the alphaThe pump is CE marked for the management of refractory ascites due to cirrhosis of the liver and malignant ascites and is included in key clinical practice guidelines. Over 900 alphapump systems have been implemented to date.

Sequana Medical has combined its proven skills alphapump and proprietary DSR therapy, and develops the alphaDSR pump, a revolutionary approach to fluid overload due to heart failure. RED DESERT has demonstrated that repeated DSR treatment in patients with diuretic-resistant heart failure is able not only to manage the water and sodium balance of these patients, but also to improve their cardio-renal status and restore their diuretic response for months after treatment. Provisional results of the ongoing SAHARA DESERT study alphaDSR pump in decompensated heart failure patients indicated safe, effective, and rapid clearance of persistent congestion and restoration of euvolemia, as well as considerable benefit on cardio-renal status and dramatic improvement in diuretic responsiveness . Main data reporting is planned for H2 2022.

Sequana Medical is headquartered in Ghent, Belgium. For more information, please visit

Important Regulatory Disclaimers

the alphapump® is not currently approved in the United States or Canada. In the United States and Canada, the alphapump is currently under clinical investigation (POSEIDON study) and is being studied in adult patients with refractory or recurrent ascites due to cirrhosis. For more information on the POSEIDON clinical study, see DSR® Therapy is still under development and it should be noted that any statements regarding safety and efficacy derive from ongoing preclinical and clinical studies which have not yet been completed. DSR therapy is not currently approved for clinical research in the United States or Canada. There is no connection between the DSR therapy and the ongoing investigations with the alphapump system in Europe, the United States or Canada.

To note: alphapump® is a registered trademark. DSR® and alphapump DSR® are registered trademarks in Benelux, China, EU, UK and Hong Kong.

Forward-looking statements

This press release may contain predictions, estimates or other information that could be considered forward-looking statements. These forward-looking statements are not guarantees of future performance. These forward-looking statements represent Sequana Medical’s current judgment of what the future holds, and are subject to risks and uncertainties that could cause actual results to differ materially. Sequana Medical expressly disclaims any obligation or undertaking to issue updates or revisions to the forward-looking statements contained in this press release, except as specifically required by law or regulation. You should not place undue reliance on forward-looking statements, which reflect the views of Sequana Medical only as of the date of this press release.


About Terry Gongora

Check Also

India and the United States have common goals and challenges that bind them, says Minister Jitendra Singh

India and the United States have common goals and challenges that bind the two nations, …